The U.S. Patent and Trademark Office has announced that it will grant a patent to MDI Biological Laboratory scientists Voot P. Yin, Ph.D., and Kevin Strange, Ph.D., and their collaborator Michael Zasloff, M.D., Ph.D., for use of the small molecule MSI-1436 to stimulate the repair and regeneration of heart tissue damaged by injuries such as a heart attack.
The patent award — the first for the MDI Biological Laboratory — represents a major step forward in moving MSI-1436 into clinical studies in humans. The MDI Biological Laboratory, located in Bar Harbor, Maine, is an independent, non-profit biomedical research institution focused on increasing healthy lifespan and increasing our natural ability to repair and regenerate tissues damaged by injury and disease.
In 2013, Strange and Yin spun off the MDI Biological Laboratory’s first for-profit company, Novo Biosciences, with the central goal of developing MSI-1436 into a novel therapeutic for treating heart and skeletal muscle diseases. The MDI Biological Laboratory has granted Novo Biosciences an exclusive license to develop MSI-1436 as a regenerative medicine therapy.
“The importance of this achievement cannot be overstated,” said Strange, president of the MDI Biological Laboratory and co-founder and CEO of Novo Biosciences. “This patent is a critical step forward in our ability to develop new treatments for those who suffer from heart disease, as well as a validation of the effectiveness of MDI Biological Laboratory’s and Novo Biosciences’ approach to drug discovery and development.”